Clonal CD27+ CD19+ B cell expansion through inhibition of FCγIIR in HCV+ cryoglobulinemic patients: A model

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 326-333

  De Re, Valli ^a   Pavan, Alessandro ^a   Sansonno, Silvia ^a   Sansonno, Domenico ^b   Racanelli, Vito ^b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

B cell clonal expansion; B cell receptor (BCR); Cryoglobulinemia; FC gamma II receptor (FC IIR); Hepatitis C virus (HCV)

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD19 ANTIGEN; CD27 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; EPITOPE; FC RECEPTOR IIA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; RHEUMATOID FACTOR;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CONFERENCE PAPER; CRYOGLOBULINEMIA; CRYOPRECIPITATION; HELPER CELL; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION SENSITIVITY; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; MEMORY CELL; PERSISTENT INFECTION; VIRUS INFECTION;

HEPATITIS C VIRUS;

EID: 70049107416     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04664.x     Document Type: Conference Paper

References (39)

1. De Re, V. et al. 2008. Mixed cryoglobulinemia syndrome as an additional autoimmune disorder associated with risk for lymphoma development. Blood 111: 5760.
2. Zignego, A.L. et al. 2008. HBV and HCV chronic infection: Autoimmune manifestations and lympho-proliferation. Authorthortoimmun. Rev. 8: 107-111.
3. Ferri, C. et al. 2007. B-cells and mixed cryoglobuline-mia. Authorthortoimmun. Rev. 7: 114-120.
4. De Re, V. et al. 2007. B-cell lymphomas associated with HCV infection. Gastroenterology 132: 1205-1207.
5. De Re, V. et al. 2000. Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process. Int. J. Cancer 87: 211-216.
6. Kawamura, Y. et al. 2007. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am. J. Med. 120: 1034-1041.
7. Gisbert, J.P. et al. 2005. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment. Pharmacol. Ther. 21: 653-662.
8. Matteucci, C. et al. 2008. Different genomic imbalances in low-and high-grade HCV-related lym-phomas. Leukemia 22: 219-222.
9. De Re, V. et al. 2007. Role of the HLA class II: HCV-related disorders. Ann. N. Y. Acad. Sci. 1107: 308-318.
10. De Vita, S. et al. 2008. Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregula-tion: targeting the infectious trigger, the autoimmune response, or both? Authorthortoimmun. Rev. 8: 95-99.
11. Giannini, C. et al. 2008. Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? Blood 112: 4353-4354.
12. Racanelli, V. et al. 2006. Antibody production and in vitro behavior of CD27-defined B-cell subsets: persistent hepatitis C virus infection changes the rules. J. V i r o l . 80: 3923-3934.
13. Klein, U. et al. 1998. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J. Exp. Med. 188: 1679-1689.
14. Atta, A.M. et al. 2007. Serum markers of rheumatoid arthritis in visceral leishmaniasis: Rheumatoid factor and anti-cyclic citrullinated peptide antibody. J. Autoimmun. 28: 55-58.
15. Charles, E.D. et al. 2007. Clonal expansion of IgM+CD27+B cells in HCV-associated mixed cryo-globulinemia. Blood 111: 1344-1356.
16. De Re, V. et al. 2000. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood 96: 3578-3584.
17. Perotti, M. et al. 2008. Hepatitis C virus (HCV)-driven stimulation of subfamily-restricted natural IgM antibodies in mixed cryoglobulinemia. Au-thorthortoimmun. Rev. 7: 468-472.
18. De Re, V. et al. 2002. Salivary gland B cell lympho-proliferative disorders in Sjogren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkin's lymphomas. Eur. J. Immunol. 32: 903-910.
19. Terrier, B. et al. 2009. Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. Ann. Rheum. Dis. 68: 89-93.
20. De Re, V. et al. 2006. Type II mixed cryoglobuli-naemia as an oligo rather than a mono B-cell disorder: evidence from GeneScan and MALDI-TOF analyses. Rheumatology (Oxford) 45: 685-693.
21. De Re, V. et al. 2006. HCV-NS3 and IgG-Fc crossre-active IgM in patients with type II mixed cryoglobu-linemia and B-cell clonal proliferations. Leukemia 20: 1145-1154.
22. Ferraccioli, G. & B. Tolusso. 2007. Infections, B cell receptor activation and autoimmunity: Different check-point impairments lead to autoimmunity, clonal B cell expansion and fibrosis in different im-munological settings. Authorthortoimmun. Rev. 7: 109-113.
23. Bende, R.J. et al. 2005. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J. Exp. Med. 201: 1229-1241.
24. De Vita, S. et al. 2000. Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis. Hepatology 31: 182-189.
25. Tamir, I. et al. 2000. The RasGAP-binding protein p62dok is a mediator of inhibitory Fcgam-maRIIB signals in B cells. Immunity 12: 347-358.
26. Brown, B.K. et al. 1999. Trafficking of the Igalpha/ Igbeta heterodimer with membrane Ig and bound antigen to the major histocompatibility complex class II peptide-loading compartment. J. Biol. Chem. 274: 11439-11446.
27. Oda, A. et al. 2008. PKC eta directs induction of IRF-4 expression and Ig kappa gene rearrangement in pre-BCR signaling pathway. Int. Immunol. 20: 1417-1426.
28. Mitchison, N.A. 2004. T-cell-B-cell cooperation. Nat. Rev. Immunol. 4: 308-312.
29. Diepolder, H.M. et al. 1997. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J. V i r o l . 71: 6011-6019.
30. Gerlach, J.T. et al. 2005. Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins. J. V i r o l . 79: 12425-12433.
31. Flobakk, M. et al. 2008. Processing of an antigenic sequence from IgG constant domains for presentation by MHC class II. J. Immunol. 181: 7062-7072.
32. De Groot, A.S. et al. 2008. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregit-opes." Blood 112: 3303-3311.
33. Fridman, W.H. et al. 1992. Structural bases of Fc gamma receptor functions. Immunol. Rev. 125: 49-76.
34. Martinsson, K. et al. 2008. The effect of activating and inhibiting Fc-receptors on murine mercury-induced autoimmunity. J. Autoimmun. 31: 22-29.
35. Nimmerjahn, F. & J.V. Ravetch. 2006. Fcgamma receptors: old friends and new family members. Immunity 24: 19-28.
36. Rahman, Z.S. & T. Manser. 2005. Failed up-regulation of the inhibitory IgG Fc receptor Fc gamma RIIB on germinal center B cells in autoimmune-prone mice is not associated with deletion polymorphisms in the promoter region of the Fc gamma RIIB gene. J. Immunol. 175: 1440-1449.
37. Moll, T. et al. 2004. A critical role for Fc gamma RIIB in the induction of rheumatoid factors. J. Immunol. 173: 4724-4728.
38. Fournier, E.M. et al. 2008. Activation of human peripheral IgM +B cells is transiently inhibited by BCR-independent aggregation of Fc gammaRIIB. J. Immunol. 181: 5350-5359.
39. Crowley, J.E. et al. 2009. Fc{gamma}RIIB signals inhibit BLyS signaling and BCR-mediated BLyS receptor upregulation. Blood 113: 1464-1473.